IL2RG and acute myeloid leukemia: To assess the effect of combination PLX51107 and dinaciclib treatment in an in vivo disseminated model of AML, we engrafted GFP/luciferase labeled MOLM-13 AML cells via tail vein injection into NOD/SCID IL2rγ−/− (NSG) mice, followed by initiation of PLX51107 20 mg/kg daily oral gavage, dinaciclib 30 mg/kg intraperitoneal injection 3 times weekly, combination, or vehicle treatment.